Two FDA Approvals in One Day: Novartis and Novo Nordisk

Published on: LinkedIn (Spencer Knight)

The FDA has approved Novartis’ Leqvio (inclisiran) as the first siRNA drug to lower LDL-C without statins, aligning with new cardiovascular guidelines. Novo Nordisk’s Alhemo (concizumab-mtci) was also approved for haemophilia A and B patients without inhibitors, expanding treatment options. These landmark approvals highlight progress in both cholesterol management and rare disease care.

👉 Read the full article: Two FDA Approvals in One Day

Disclaimer:

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.